tiprankstipranks
Trending News
More News >
IDEAYA Biosciences (IDYA)
NASDAQ:IDYA
Advertisement

IDEAYA Biosciences (IDYA) AI Stock Analysis

Compare
614 Followers

Top Page

IDYA

IDEAYA Biosciences

(NASDAQ:IDYA)

Select Model
Select Model
Select Model
Neutral 56 (OpenAI - 4o)
Rating:56Neutral
Price Target:
$29.00
▲(2.04% Upside)
IDEAYA Biosciences' overall stock score is primarily influenced by its financial performance and technical analysis. The company faces financial challenges with declining revenues and consistent net losses, impacting its financial performance score. However, the stock shows positive technical momentum, which partially offsets financial concerns. Valuation remains a challenge due to negative earnings and lack of dividends.
Positive Factors
Strong Clinical Data
The promising clinical trial results for darovasertib in uveal melanoma highlight IDEAYA's potential to address unmet medical needs, enhancing its market position and long-term growth prospects in oncology.
Strategic Partnerships
Strategic partnerships provide IDEAYA with financial support and access to resources necessary for efficient drug development, bolstering its ability to advance its pipeline and enhance long-term growth.
Low Leverage
A low debt-to-equity ratio suggests financial stability and flexibility, allowing IDEAYA to invest in R&D and strategic initiatives without the burden of high-interest obligations.
Negative Factors
Declining Revenue
A significant decline in revenue indicates challenges in commercializing products, which may affect IDEAYA's ability to sustain operations and invest in future growth.
Negative Cash Flow
Negative cash flow from operations suggests that IDEAYA is not generating sufficient cash from its core activities, potentially impacting its ability to fund R&D and operational expenses.
Profitability Challenges
Persistent profitability challenges highlight operational inefficiencies and may hinder IDEAYA's ability to achieve sustainable financial performance, impacting long-term viability.

IDEAYA Biosciences (IDYA) vs. SPDR S&P 500 ETF (SPY)

IDEAYA Biosciences Business Overview & Revenue Model

Company DescriptionIDEAYA Biosciences (IDYA) is a biotechnology company focused on the discovery and development of targeted therapeutics for cancer and other genetic diseases. The company specializes in precision medicine, leveraging its proprietary drug discovery platforms to identify and develop small molecule therapeutics that target specific genetic mutations and pathways. IDEAYA operates primarily in the oncology sector and is committed to advancing innovative treatment options for patients with unmet medical needs.
How the Company Makes MoneyIDEAYA Biosciences generates revenue through a combination of its own product development efforts and strategic partnerships. The company primarily earns money by advancing its pipeline of drug candidates through various stages of clinical trials, leading to potential commercialization. Additionally, IDEAYA enters into collaborations and licensing agreements with larger pharmaceutical companies, which can provide upfront payments, milestone payments based on development progress, and royalties on future sales. These partnerships not only offer financial support but also access to resources and expertise necessary for efficient drug development. The company may also receive funding through grants and investments to support its research initiatives.

IDEAYA Biosciences Financial Statement Overview

Summary
IDEAYA Biosciences faces significant financial challenges with declining revenues and consistent net losses. The company maintains a strong equity position, suggesting stability, but profitability and cash flow constraints pose risks. Strategic improvements are necessary for future growth.
Income Statement
42
Neutral
The company has seen a significant decline in revenue over the past year, with a negative growth rate of 70%. Gross profit margin remains at 100% due to no cost of goods sold reported. However, high negative net profit, EBIT, and EBITDA margins reflect operational challenges and lack of profitability.
Balance Sheet
55
Neutral
IDEAYA Biosciences maintains a strong equity base, with an equity ratio of 94%. The debt-to-equity ratio is low, indicating minimal leverage, but return on equity is negative due to net losses, highlighting profitability challenges.
Cash Flow
48
Neutral
Operating cash flow and free cash flow are both negative, indicating cash burn from operations. However, the company has managed substantial financing activities, improving cash reserves significantly, albeit not enough to cover the free cash flow deficit.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue7.00M7.00M23.39M50.93M27.94M19.54M
Gross Profit6.36M7.00M19.38M48.83M26.22M-20.16M
EBITDA-382.45M-326.98M-130.42M-60.40M-48.54M-33.96M
Net Income-331.03M-274.48M-112.96M-54.81M-47.53M-32.27M
Balance Sheet
Total Assets1.04B1.12B649.32M387.97M381.35M298.27M
Cash, Cash Equivalents and Short-Term Investments669.74M676.32M525.11M373.15M368.06M283.58M
Total Debt26.60M19.17M2.87M3.48M5.18M6.72M
Total Liabilities81.62M64.94M28.23M387.97M381.35M298.27M
Stockholders Equity959.65M1.06B621.09M349.45M301.51M198.27M
Cash Flow
Free Cash Flow-297.26M-251.44M-117.59M-90.62M-58.42M54.97M
Operating Cash Flow-293.70M-247.58M-115.22M-87.17M-55.78M55.46M
Investing Cash Flow-91.41M-502.56M-158.46M-33.40M-69.67M-146.24M
Financing Cash Flow316.61M677.55M362.72M97.17M145.45M128.75M

IDEAYA Biosciences Technical Analysis

Technical Analysis Sentiment
Positive
Last Price28.42
Price Trends
50DMA
26.09
Positive
100DMA
24.34
Positive
200DMA
22.06
Positive
Market Momentum
MACD
0.86
Negative
RSI
56.85
Neutral
STOCH
53.31
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IDYA, the sentiment is Positive. The current price of 28.42 is above the 20-day moving average (MA) of 27.68, above the 50-day MA of 26.09, and above the 200-day MA of 22.06, indicating a bullish trend. The MACD of 0.86 indicates Negative momentum. The RSI at 56.85 is Neutral, neither overbought nor oversold. The STOCH value of 53.31 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IDYA.

IDEAYA Biosciences Risk Analysis

IDEAYA Biosciences disclosed 77 risk factors in its most recent earnings report. IDEAYA Biosciences reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

IDEAYA Biosciences Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
62
Neutral
$2.52B3.7864.05%30.57%
56
Neutral
$2.56B-35.09%-41.48%-73.55%
55
Neutral
$2.45B-705.73%87.94%57.84%
54
Neutral
$2.47B-57.33%99.50%65.91%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
51
Neutral
$3.02B-41.94%-82.90%-155.64%
44
Neutral
$2.97B-134.54%-25.61%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IDYA
IDEAYA Biosciences
28.42
-0.88
-3.00%
AGIO
Agios Pharma
42.09
-3.00
-6.65%
TVTX
Travere Therapeutics
28.15
10.62
60.58%
CELC
Celcuity
70.57
54.96
352.08%
ARQT
Arcutis Biotherapeutics
20.08
11.33
129.49%
BEAM
Beam Therapeutics
28.20
6.65
30.86%

IDEAYA Biosciences Corporate Events

Product-Related Announcements
IDEAYA Biosciences Presents Promising Phase 2 Data
Positive
Oct 20, 2025

On October 17, 2025, IDEAYA Biosciences announced positive median overall survival data from its Phase 1/2 trial of darovasertib combined with Pfizer’s crizotinib for first-line treatment of metastatic uveal melanoma, showing a median OS of 21.1 months. Additionally, on October 20, 2025, IDEAYA presented promising Phase 2 data for darovasertib in the neoadjuvant setting of primary uveal melanoma, demonstrating significant tumor shrinkage and eye preservation, with manageable safety profiles.

The most recent analyst rating on (IDYA) stock is a Buy with a $64.00 price target. To see the full list of analyst forecasts on IDEAYA Biosciences stock, see the IDYA Stock Forecast page.

Ideaya Biosciences Advances IDE849 Study for DLL3-Expressing Tumors
Sep 26, 2025

Ideaya Biosciences is conducting a clinical study titled ‘A Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of IDE849 in Patients With DLL3-Expressing Tumors Including Small Cell Lung Cancer.’ The study aims to assess the safety and effectiveness of IDE849, a potential treatment for tumors expressing DLL3, particularly small cell lung cancer (SCLC). This research is significant as it explores new therapeutic options for a challenging cancer type.

Product-Related Announcements
IDEAYA Biosciences Reports Promising Phase 1 Data for IDE849
Positive
Sep 8, 2025

IDEAYA Biosciences, in collaboration with Jiangsu Hengrui Pharmaceuticals, presented promising Phase 1 data for IDE849, a DLL3-targeting TOP1 ADC, at the IASLC 2025 World Conference on Lung Cancer. The trial showed a robust overall response rate and disease control rate in small cell lung cancer patients, with manageable safety profiles across various dose levels. Additionally, IDEAYA shared positive interim results from its Phase 2 trial of darovasertib for primary uveal melanoma, demonstrating significant tumor shrinkage and improved visual outcomes. The company also reported encouraging data from its Phase 1/2 trial of IDE397 combined with Trodelvy in MTAP-deletion urothelial cancer, highlighting a favorable safety profile and notable response rates.

The most recent analyst rating on (IDYA) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on IDEAYA Biosciences stock, see the IDYA Stock Forecast page.

Ideaya Biosciences Advances in Metastatic Uveal Melanoma Treatment Study
Sep 7, 2025

Ideaya Biosciences is conducting a clinical study titled ‘IDE196 (Darovasertib) in Combination With Crizotinib Versus Investigator’s Choice of Treatment as First-line Therapy in HLA-A2 Negative Metastatic Uveal Melanoma (DAR-UM-2).’ The study aims to evaluate the efficacy of IDE196 combined with Crizotinib compared to standard treatments for patients with metastatic uveal melanoma, a rare eye cancer. This research is significant as it explores a new potential first-line treatment option for this challenging condition.

Business Operations and StrategyProduct-Related Announcements
IDEAYA Biosciences Licenses Darovasertib to Servier
Positive
Sep 2, 2025

On August 29, 2025, IDEAYA Biosciences entered into a License Agreement with Les Laboratoires Servier, granting Servier exclusive rights to develop and commercialize darovasertib outside the United States. This agreement includes an upfront payment of $210 million to IDEAYA, with potential additional milestone payments and royalties, extending the company’s cash runway by at least twelve months and funding operations into 2030. The agreement outlines conditions for termination and includes customary transaction provisions.

The most recent analyst rating on (IDYA) stock is a Hold with a $27.00 price target. To see the full list of analyst forecasts on IDEAYA Biosciences stock, see the IDYA Stock Forecast page.

GSK and Ideaya’s Promising Study on Solid Tumors: A Potential Game-Changer?
Aug 8, 2025

GlaxoSmithKline (GSK) and Ideaya Biosciences are conducting a study titled A Phase 1/2 First-Time-in-Human, Open-label, Multicenter, Dose Escalation and Expansion Study of the Oral DNA Helicase Werner Inhibitor (WRNi) GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Adult Participants With Mismatch Repair-deficient (dMMR) or Microsatellite Instability-High (MSI-H) Solid Tumors (SYLVER). The study aims to evaluate the safety, pharmacokinetics, and preliminary effectiveness of GSK4418959, alone or with a PD-1 inhibitor, in treating aggressive solid tumors with specific genetic traits.

GSK and Ideaya’s Promising Study on Tumor-Reducing Drug GSK4418959
Aug 6, 2025

GlaxoSmithKline (GSK) and Ideaya Biosciences are conducting a study titled ‘A Phase 1/2 First-Time-in-Human, Open-label, Multicenter, Dose Escalation and Expansion Study of the Oral DNA Helicase Werner Inhibitor (WRNi) GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Adult Participants With Mismatch Repair-deficient (dMMR) or Microsatellite Instability-High (MSI-H) Solid Tumors (SYLVER)’. The study aims to evaluate the safety, pharmacokinetics, and preliminary effectiveness of GSK4418959, alone or combined with a PD-1 inhibitor, in reducing tumor size in participants with specific genetic tumor characteristics.

IDEAYA Biosciences Reports Q2 2025 Financial Results
Aug 6, 2025

IDEAYA Biosciences, Inc. is a precision medicine oncology company focused on developing transformative therapies for cancer, leveraging expertise in small-molecule drug discovery and antibody-drug conjugates to address molecularly defined solid tumor indications.

Ideaya Biosciences Advances in Ocular Melanoma Treatment with Darovasertib Study
Aug 4, 2025

Ideaya Biosciences is conducting a clinical study titled (Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma. The study aims to evaluate the effectiveness of IDE196 (darovasertib), a drug designed to treat primary uveal melanoma, a rare eye cancer. This study is significant as it explores a potential new treatment option for a condition with limited therapies.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Oct 23, 2025